이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Anhui Anke Biotechnology (Group) 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lihua Song

최고 경영자

CN¥2.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	31.2yrs
CEO 소유권	26.6%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

May 23

Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Mar 01

CEO

Lihua Song (67 yo)

31.2yrs

테뉴어

CN¥2,712,000

보상

Mr. Song Lihua serves as the Chairman of the Board and President at Anhui Anke Biotechnology (Group) Co., Ltd and its Director since May 1, 1993.

리더십 팀

이름	위치	테뉴어	보상	소유권
Lihua Song	Chairman of Board of Directors & President	no data	CN¥2.71m	26.57% CN¥ 3.8b
Chenghao Hu	Financial Director	less than a year	CN¥438.70k	0.0024% CN¥ 341.3k
Jian Ping Yao	Executive President	no data	CN¥857.00k	0.40% CN¥ 57.7m
Hai Sheng	Senior Vice President	no data	CN¥1.11m	0.23% CN¥ 32.8m
Hui Zhao	Senior VP & Director	no data	CN¥651.00k	0.61% CN¥ 87.4m
Chunyan Lu	Vice President	less than a year	CN¥506.00k	0.020% CN¥ 2.9m
Yuanyuan Zhou	VP & Director	2.1yrs	CN¥635.00k	0.13% CN¥ 18.8m
Hongyi Yao	Vice President	1.3yrs	CN¥531.00k	0.048% CN¥ 6.9m
Xueke Bao	Vice President	less than a year	CN¥1.10m	0.025% CN¥ 3.5m
Yinghui Dou	Vice President	1.6yrs	CN¥687.00k	0.024% CN¥ 3.4m
Tawei Chou	Vice President	less than a year	CN¥887.00k	0.0087% CN¥ 1.2m
Kun Li	Secretary of the Board & Director	4.6yrs	CN¥469.00k	0.022% CN¥ 3.1m

1.0yrs

평균 재임 기간

49.5yo

평균 연령

경험이 풍부한 관리: 300009 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lihua Song	Chairman of Board of Directors & President	31.2yrs	CN¥2.71m	26.57% CN¥ 3.8b
Hui Zhao	Senior VP & Director	17.3yrs	CN¥651.00k	0.61% CN¥ 87.4m
Yuanyuan Zhou	VP & Director	1.6yrs	CN¥635.00k	0.13% CN¥ 18.8m
Kun Li	Secretary of the Board & Director	1.6yrs	CN¥469.00k	0.022% CN¥ 3.1m
Xian Yu Du	Director	less than a year	CN¥72.00k	0.039% CN¥ 5.6m
Li Ming Song	Vice Chairman of the Board	20.9yrs	CN¥976.00k	6.87% CN¥ 981.2m
Yong Bin Wang	Director	10.7yrs	CN¥501.00k	0.072% CN¥ 10.3m
Guang Fu Liu	Independent Director	4.6yrs	CN¥75.00k	데이터 없음
Wei Dong Zhu	Independence Director	4.6yrs	CN¥75.00k	데이터 없음
Junpei Jiang	Director	1.6yrs	CN¥501.50k	0.058% CN¥ 8.3m
Feihu Chen	Independent Director	1.6yrs	CN¥75.00k	데이터 없음
Xiaoping Geng	Independent Director	1.6yrs	CN¥75.00k	데이터 없음

3.1yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: 300009 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Anhui Anke Biotechnology (Group) 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Board Elections

Less than half of directors are independent

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 20, 2022

Recent updates

Anhui Anke Biotechnology (Group) Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Anhui Anke Biotechnology (Group) (SZSE:300009) Will Pay A Dividend Of CN¥0.25

Dividend of CN¥0.25 announced

First quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 1Q 2023)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Working Against Anhui Anke Biotechnology (Group) Co., Ltd.'s (SZSE:300009) Share Price

Investor sentiment improves as stock rises 20%

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2023 Results on Mar 28, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.15 in 3Q 2022)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.10 in 2Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Board Elections

Investor sentiment improved over the past week

Price target decreased to CN¥18.92

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.075 in 2Q 2021)

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Cash Dividend for the Year 2021, Payable on 13 May 2022

Price target decreased to CN¥18.92

First quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.075 in 1Q 2021)

Less than half of directors are independent

Anhui Anke Biotechnology (Group) Co., Ltd. Approves Profit Distribution

Full year 2021 earnings: EPS and revenues miss analyst expectations

Anhui Anke Biotechnology (Group) Co., Ltd., Annual General Meeting, Apr 20, 2022

Anhui Anke Biotechnology (Group) Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Anhui Anke Biotechnology (Group) Co., Ltd. (SZSE:300009) announces an Equity Buyback for CNY 60 million worth of its shares.

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.084 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.075 (vs CN¥0.049 in 2Q 2020)

Investor sentiment deteriorated over the past week

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented for 2020 (A Shares), Payable on 14 May 2021

First quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.062 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.092 in FY 2019)

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Fiscal Year 2020 Results on Apr 08, 2021

New 90-day low: CN¥13.69

New 90-day low: CN¥14.64

New 90-day low: CN¥14.71

New 90-day low: CN¥15.69

Third quarter earnings released

Earnings released

New 90-day high - CN¥20.86

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령